人滋养细胞表面抗原（Trop-2）在病变子宫内膜中表达的研究

摘要 目的：探讨人滋养细胞表面抗原（trophoblast cell-surface antigens2,Trop-2）在病变子宫内膜中的表达及其临床相关性。方法：采用免疫组化法检测100例正常子宫内膜或病变子宫内膜组织中Trop-2蛋白的表达,其中单纯增生子宫内膜患者26例,复杂或不典型增生子宫内膜患者34例,子宫内膜腺癌患者20例,对照组为20例增生期子宫内膜患者。结果：免疫组织化学法研究结果显示,Trop-2蛋白在正常增生子宫内膜和单纯性增生子宫内膜中几乎不表达,在复杂或不典型增生子宫内膜组织中以及子宫内膜腺癌呈阳性表达。主要分布在细胞膜上,阳性率分别为35.29 %和65.00 %,经过对比子宫内膜癌组的阳性表达率显著高于复杂型或伴不典型增生子宫内膜组的阳性表达率（P<0.05）,且复杂型或伴不典型增生子宫内膜组的阳性表达率显著高于单纯性增生子宫内膜组（P<0.05）,其表达水平随内膜病变程度的加重而升高,呈正相关关系（P＜0.05）。结论：Trop-2蛋白在子宫内膜病变中的表达与其严重程度一致,可反映子宫内膜病变的发生发展,或可作为判断其严重程度的指标。     

子宫内膜异位症患者血清VEGF和CRP水平变化及其相关性

目的：探讨子宫内膜异位症患者血清血管内皮生长因子（VEGF）和C-反应蛋白（CRP）的水平变化及其相关性。方法：采用ELISA的方法测定30例III～Ⅳ期子宫内膜异位症患者（其中增生期13例、分泌期17例）和22例非子宫内膜异位症患者（其中增生期10例、分泌期12例）血清VEGF和CRP的水平,并分析两者相关性。结果：子宫内膜异位症组分泌期血清VEGF水平明显高于对照组（P〈0．05）;子宫内膜异位症组增生期血清CRP水平明显高于对照组（P〈0．05）;子宫内膜异位症组增生期和分泌期血清VEGF与CRP水平存在显著的正相关（F0．52,P〈0．05;r=0．44,P〈0．05）。结论：子宫内膜异位症患者血清VEGF、CRP水平的升高说明了过度血管生成和异常炎症反应是子宫内膜异位症的显著特征。     

原发不育症子宫内膜花生凝集素受体的研究

本文以PNA(花生凝集素)为探针,应用ABC亲和组化技术,对69例原发不育症患者的子宫内膜PNA受体进行了检测.结果表明,原发不育症子宫内膜的增生期、分泌期PNA受体的阳性率均显著低于年龄相似、有生育史的对照组子宫内膜的阳性率.不育症子宫内膜分泌欠佳的PNA受体阳性率显著低于不育症分泌期不同时期子宫内膜的阳性率.提示,这种差异可能与雌孕激素对两组子宫内膜作用水平的不同引起.     

MUC16对子宫内膜容受性的影响及其意义

目的：多囊卵巢综合征（Polycystic Ovary Syndrome,PCOS）系由于体内复杂的内分泌和代谢环境影响了子宫内膜稳态,导致子宫内膜容受性下降,造成患者生育力减弱和不良妊娠结局。通过测定多囊卵巢综合征患者子宫内膜与正常生育力妇女增生期、分泌早、中、晚期子宫内膜中MUC16的相对表达量,本文探讨MUC16与PCOS患者子宫内膜容受性下降的关系,为临床上改善PCOS患者子宫内膜容受性,提高PCOS患者的妊娠率,降低流产率提供一条新的可能途径。方法：选择PCOS患者子宫内膜、正常生育力妇女增生期、分泌早、中、晚期子宫内膜各20例,用免疫组化SP法检测MUC16在各组的表达情况。结果：（1）MUC16在月经周期各期均有表达,在分泌中期表达最强。（2）PCOS组MUC16的表达较分泌中期组弱,差异有显著性（P〈0.05）。结论：（1）在子宫内膜中的表达呈周期性变化。（2）PCOS患者子宫内膜中MUC16表达异常可能使子宫内膜容受性下降,推测其与胚胎不能正常着床或着床后发育不良、导致流产有关。     

同期发情处理小鼠与自然发情小鼠子宫内膜中孕激素受体分布的比较

目的从孕激素受体（PR）的角度探讨同期发情处理与自然发情小鼠的子宫内膜上,孕激素受体分布是否受内源孕激素的特异诱导而变化,两者之间是否存在差异。方法27只同日龄母鼠,根据处理方式的不同随机分为三个组：自然发情假孕组（对照组）、同期发情处理假孕组和自然发情假孕第l天摘除卵巢组,3个组的小鼠在见栓后第4、6、8天分别取样后,采用免疫组织化学法观察小鼠子宫内膜中孕激素受体的分布情况。结果免疫组化结果显示,三个处理组小鼠子宫内膜的三种细胞中都有PR存在;见栓第4天时,同期发情处理组小鼠子宫腺上皮细胞和基质细胞的PR胞核阳性率显著高于自然发情组（P〈0．05）;见栓第6天时,同期发情处理组小鼠子宫内膜三种细胞中的PR胞核阳性率显著高于自然发情组（P〈0．05）;同时自然发情假孕第1天摘除卵巢组在见栓第6和8天时的阳性率均显著低于其它两组（P〈0．05）。结论同期发情处理的小鼠子宫内膜中孕激素受体分布显著高于自然发情小鼠,且两者都受其内源性孕激素的特异诱导而变化。     

曼月乐与妇康片治疗单纯性子宫内膜增生的临床疗效比较

目的:比较曼月乐与妇康片治疗单纯性子宫内膜增生(simple endometrial hyperplasia,SHE)的临床疗效.方法:选择SHE患者102例,在患者知情同意自愿的前提下,分为妇康片组(n=46例)和曼月乐组(n=56例),妇康片组给予妇康片治疗,曼月乐组给予曼月乐治疗,比较两组患者治疗3个月后的临床疗效、PBAC评分、子宫内膜厚度、血红蛋白水平,同时记录并比较两组患者在治疗过程中不良反应的发生情况.结果:治疗3个月后,两组患者显效例数与无效例数比较,差异具有统计学意义(P＜0.05);曼月乐组患者PBAC评分、子宫内膜厚度均显著低于妇康片组,而血红蛋白水平显著高于妇康片组,差异均具有统计学意义(P＜0.05);治疗期间出现肝肾功能异常例数比较,差异具有统计学意义(P＜0.05),曼月乐组均优于妇康片组.结论:曼月乐治疗SHE的疗效较妇康片更好,并能减少不良反应.     

宫腔镜下电切术与刮宫术治疗子宫内膜息肉合并不孕症的疗效比较及术后妊娠的影响因素分析

摘要 目的：比较宫腔镜下电切术与宫腔镜下刮宫术治疗子宫内膜息肉合并不孕症的疗效,并分析术后妊娠的影响因素。方法：选取2018年10月～2020年9月我院收治的318例子宫内膜息肉合并不孕症患者,其中接受宫腔镜下电切术治疗的159例归为电切术组,接受宫腔镜下刮宫术治疗的159例归为刮宫术组,术后均随访12个月,比较两组手术相关指标、子宫内膜厚度、月经量和围术期并发症、息肉复发率、临床妊娠率,多因素Logistic回归分析术后妊娠的影响因素。结果：电切术组术中出血量低于刮宫术组（P＜0.05）,两组患者手术时间、住院时间比较无差异（P＞0.05）。两组患者术后12个月子宫内膜厚度较术前降低,且电切术组术后子宫内膜厚度低于刮宫术组（P＜0.05）。两组患者术后1个月、术后3个月月经量较术前逐渐减少,且电切术组较刮宫术组变化更明显（P＜0.05）。电切术组息肉复发率低于刮宫术组,而临床妊娠率高于刮宫术组（P＜0.05）,两组患者围术期并发症总发生率比较差异无统计学意义（P＞0.05）。多因素Logistic回归分析结果显示,年龄≥35岁、多发息肉、息肉直径≥1 cm、宫角息肉、术后子宫内膜厚度≥13 mm、术后息肉复发是影响子宫内膜息肉合并不孕症患者术后妊娠的危险因素（P＜0.05）。结论：宫腔镜下电切术治疗子宫内膜息肉合并不孕症患者疗效较宫腔镜下刮宫术更为显著,其术后妊娠率受年龄、息肉类型、息肉直径、息肉部位、术后子宫内膜厚度、术后息肉复发等因素影响。     

雌激素受体α基因多态性及其表达与子宫内膜增生的关系

目的:探讨子宫内膜增生症雌激素受体α(estrogen receptorα,ERα)基因多态性及其与表达的关系.方法:选择江西地区150例子宫内膜增生症患者为实验组,100例子宫内膜正常妇女为对照组.应用分子生物学的方法分析ERα基因Xba Ⅰ和PvuⅡ限制性片段长度多态性,通过逆转录-多聚酶链反应(RT-PCR)和Western blot方法分析ERα表达.结果:(1)X等位基因频率的变化与子宫内膜增生程度具有相关性P＜0.01,不典型增生组中XX型频率是正常组的4倍.随着子宫内膜增生程度的增加,P等位基因频率减少,人群中PP基因型频率逐渐减少;(2)单纯性增生、复杂性增生ERαmRNA和蛋白表达均比正常组高(P＜0.01),而不典型增生ERαmRNA和蛋白质表达均比单纯增生、复杂增生低(P＜0.01).结论:ERα基因多态性与子宫内膜增生发生及增生程度存在相关性.ERα表达的下调与子宫内膜不典型增生的发生有关.     

宫腔镜切除术联合LNG-IUS治疗子宫内膜息肉的临床作用研究

摘要 目的：探讨宫腔镜息肉切除术联合LNG-IUS治疗EP的临床作用机制。方法：选取我院妇产科在2019年12月至2020年12月收治的60例EP患者作为研究对象,根据手术方式分为对照组与联合组,每组30例。对照组采用宫腔镜下息肉切除术治疗,联合组以对照组为基础,联合LNG-IUS治疗。对比两组患者临床疗效,治疗后子宫内膜厚度、复发率、内分泌激素（ER、PR）以及炎症相关因子（VEGF、TGF-β1、TNF-α、CRP、IL-6）变化情况。结果：术后,联合组总有效率优于对照组（P<0.05）;术前,两组患者子宫内膜厚度对比无差异（P＞0.05）。与术前相比,术后两组患者子宫内膜厚度减小。联合组术后各阶段子宫内膜厚度均较对照组小（P<0.05）;术前,两组患者各项指标水平变化无明显差异（P＞0.05）。术后,联合组VEGF、TGF-β1、TNF-α、CRP、IL-6、ER、PGR水平均优于对照组（P<0.05）;术后12个月内,联合组总复发率为6.66%,对照组总复发率为33.33%,联合组优于对照组（P<0.05）。结论：宫腔镜电切术联用LNG-IUS其机制可能与下调ER、PR、VEGF、TGF-β1、TNF-α、CRP、IL-6的表达水平有关,提高子宫内膜息肉治疗效果,降低复发率,为EP的诊疗及相关机制研究提供理论依据。     

The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study

In this article, we present the results of organ-preserving treatment applied in 24 patients of reproductive age with atypical endometrial hyperplasia or early-stage endometrial cancer. All of them would like to preserve their reproductive potential. Thirteen women with atypical endometrial hyperplasia were treated with the combination of six intramuscular injections of 3.75 mg gonadotropin-releasing hormone agonist (GnRHa)--leuproreline acetate depot every 4 weeks. After the third injection of 3.75 mg of leuproreline acetate, the levonorgestrel intrauterine hormonal system containing 52 mg levonorgestrel (Mirena(?), Bayer, Germany) was inserted for at least 6 months. In 11 women with stage IA well-differentiated endometrial adenocarcinoma, hormonal therapy included nine intramuscular injections of 3.75 mg of GnRHa every 4 weeks. After the third injection of 3.75 mg of GnRHa, we also inserted a GnRH-IUS (Mirena(?)) for at least 12 months. This type of therapy was effective for all these patients and may be offered to be used as an alternative to surgery in women with atypical endometrial hyperplasia or early stage 1A well-differentiated endometrial cancer in women of reproductive age. Three women with endometrial cancer became pregnant and two of them delivered at term and one has an ongoing pregnancy.     

Endometrial disease after treatment with oestrogens and progestogens in the climacteric.

A prospective study of 745 women receiving different regimens of hormone treatment for the climacteric for a total of 21 736 months was performed. There was a lower incidence of endometrial hyperplasia in biopsy specimens in the women receiving cyclical low-dose oestrogen by mouth than in those receiving cyclical high-dose oestrogen by mouth. The incidence of abnormalities in the women receiving sequential oestrogen and progestogen was lower than in either of these two groups. Among the women receiving subcutaneous oestrogen implants the incidence was higher still, but over half of the abnormal specimens were from women who had not taken their progestogen. The incidence of hyperplasia fell with longer courses of progestogen, and no hyperplasia was found in patients taking progestogen for over 10 days each month. The incidence of adenomatous and atypical hyperplasia is significantly reduced by a progestogen when taken for 10 or more days monthly. The absence of vaginal bleeding or of a regular bleeding response does not guarantee histologically normal endometrium in patients taking oestrogens without progestogen.     

Direct effect of danazol on endometrial hyperplasia in adenomyotic women: treatment with danazol containing intrauterine device

It is well known that danazol has a direct effect on endometriosis tissue and cell. We have been treating adenomyotic women with danazol containing intrauterine device (D-IUD) from June 1993 to August 2000 and significant decrease of dysmenorrhea and serum CA-125 levels were observed. Of fifty-nine adenomyotic women, eight women were also diagnosed by endometrial biopsy as endometrial hyperplasia and one woman was diagnosed as atypical endometrial hyperplasia. In these endometrial hyperplastic patients, endometrial tissues were obtained before insertion and at the time of removal or exchange of D-IUD and examined pathologically. In all of the 9 women, histopathological findings of endometrial hyperplasia disappeared after D-IUD treatment. In particular, in one patient, findings of atypical endometrial hyperplasia also disappeared after D-IUD treatment. She is now closely observed at our clinic using D-IUD. By these evidences, we postulate that D-IUD is one of the treatment choices of endometrial hyperplasia given exposure of the endometrium to such an extraordinary high concentration of danazol released by D-IUD and avoidance of adverse effects of oral danazol or general administration of GnRH and progesterone. In particular, in atypical endometrial hyperplasia case, its mechanisms might give great benefit to patient. However, mechanisms of direct effect of danazol on endometrial hyperplasia remain to be elucidated in the future study.     

钙网质蛋白在多囊卵巢综合征大鼠子宫内膜的表达及意义

目的：研究钙网质蛋白（CRT）在PCOS大鼠子宫内膜中的表达及生物学意义。方法：60只雌性SD大鼠随机分为PCOS组和对照组,每组各30只。给模型组24日龄大鼠皮下埋植左旋甲基炔诺酮硅胶棒3mm／只,3d后BID皮下注射人绒毛膜促性腺激素1．5IU。给对照组皮下注射等体积生理盐水。注射9d后观察大鼠卵巢形态学（HE染色）,化学发光法测定性激素水平。结果：模型组大鼠卵巢重量和体积均显著高于对照组（P〈0．01）。模型组大鼠卵巢出现类多囊卵巢综合征的改变。模型组卵巢各级发育期卵泡及黄体少见,卵泡多呈囊性扩张。模型组大鼠血清孕激素、睾酮、空腹胰岛素、空腹血糖水平均显著高于对照组（P〈0．05）;卵泡刺激素（FSH）水平显著低于对照组（P〈0．05）。LH／FSH比值显著高于对照组（P〈0．05）。采用免疫组织化学方法及灰度值测定,定量分析CRT在PCOS组和对照组的子宫内膜中表达。CRT在两组中的子宫内膜中均有表达。PCOS组子宫内膜上皮CRT表达显著低于对照组（P〈0．01）。结论：避孕硅胶棒联合hCG诱导SD大鼠多囊卵巢综合征模型是较好的PCOS模型。CRT与PCOS的发病密切相关．     

TURis-Bt术前膀胱灌注表柔比星治疗NMIUC的临床疗效观察

目的:探讨TURis-Bt术前膀胱灌注表柔比星治疗非肌层浸润性膀胱癌(NMIUC)的临床疗效。方法:选取2008年9月至2012年1月潍坊市中医院和上海交通大学附属第一人民医院泌尿外科收治的76例NMIUC患者,并将其随机分为观察组(TURis-Bt术前膀胱灌注表柔比星+术后常规灌注组)41例和对照组(TURis-Bt术后常规表柔比星膀胱灌注组)35例。灌注前将50mg表柔比星溶解于50ml 5%葡萄糖注射液,术前膀胱保留灌注30分钟后膀胱镜观察肿瘤组织及周围膀胱粘膜染色情况,将表柔比星橙染的膀胱粘膜活检并行TURis-Bt;对照组取瘤旁2 cm处及其他部位膀胱粘膜多点活检。比较两组的原位癌(CIS)、非典型性增生及腺性膀胱炎等病变检出率和术后肿瘤的复发率。结果:观察组患者瘤旁膀胱粘膜橙染56处,其中7处病理证实为膀胱原位癌、5处为非典型性增生、11处为腺性膀胱炎;对照组患者膀胱原位癌1处、非典型性增生3处、腺性膀胱炎2处,两组病变阳性率分别为41.1%(23/56)和13.4%(17/127),差异有显著统计学意义(P0.01)。观察组与对照组术后2年内肿瘤复发率分别为10.3%(4/39)和35.3%(12/34),差异有统计学意义(P0.05)。结论:TURis-Bt术前膀胱灌注表柔比星能提高NMIUC病变的早期检出率并降低肿瘤术后复发率。     

亚麻籽木酚素预防乳腺癌及与雌激素的关系

目的通过卵巢切除术建立雌性大鼠去势模型,探究亚麻籽粉木酚素预防乳腺癌的功能及与雌性激素的关系。方法将48只雌性Wistar大鼠随机分为基础饲料组（BD）、基础饲料去势组（BDC）、亚麻籽粉组（FS）和亚麻籽粉去势组（FSC）,每组12只,对全部大鼠进行二甲基苯蒽（DMBA）一次性灌胃（2mg/kg体重）建立诱发的乳腺癌实验动物模型;一周后对BDC组、FSC组大鼠行去势手术,连续观察21周,测定瘤体的体积和重量,并取乳腺组织进行病理学检查。结果实验期间动物一般状况良好,实验组大鼠未出现明显毒副作用;亚麻籽粉组（FS和FSC组）大鼠发生可触及肿瘤的时间较相应对照组晚2到4周;亚麻籽粉组大鼠单纯性增生和不典型增生以及乳腺癌发生率和病灶数均显著低于相应对照组（单纯性增生：FS vs BD,P=0.006＊＊;FSC vs BDC,P〈0.001＊＊;不典型增生：FS vs BD,P=0.048＊;FSC vs BDC,P=0.014＊;乳腺癌：FS vs BD,P=0.028＊;FSC vs BDC,P〈0.047＊）;亚麻籽粉组大鼠肿瘤体积和重量均小于基础饲料组;FS和FSC组研究结果提示亚麻籽粉木酚素抑制增生发生及肿瘤细胞的生长的能力与实验动物体内雌性激素水平有关（单纯性增生：P=0.008＊＊;不典型增生：P=0.042＊;乳腺癌：P=0.033＊）。结论亚麻籽粉木酚素可有效预防和降低化学诱癌剂DMBA所诱发的乳腺癌、癌前病变和单纯性增生的发生,预防乳腺癌的功能和效果受到体内雌性激素影响。本研究结果对未来实施木酚素预防乳腺癌及有效人群的筛选具有参考价值。     

乳腺导管上皮内瘤变32例影像诊断分析

目的：探讨全数字化乳腺X线摄影与磁共振成像检查相结争对乳腺导管上皮内瘤变（DIN）的诊断价值。方法：对32例经乳腺平板数字X线摄影及磁共振检查并且病理证实为乳腺导管上皮内瘤变的病例进行回顾性分析。结果：32例DIN中,普通导管上皮增生（UDH）17例,DIN1A2例;DIN1B1例;乳腺导管原位癌（DIN1C--DIN3）12例。采用全数字化X线乳腺摄影与MRI相结合诊断乳腺增生18例,乳腺导管原位癌11例,3例未能明确诊断。结论：平板数字X线乳腺摄影及磁共振成像综合诊断,对乳腺导管原位癌的旱期发现具有重要意义．显著提高患者的生存质量。     

Claudin-7和β-catenin在正常、增生和恶性子宫内膜组织中的表达和意义

目的恶性肿瘤转移过程与细胞间粘附作用的丧失密切相关。本研究旨在探讨细胞间粘附分子claudin-7和β-catenin在正常、增生和恶性子宫内膜组织中的表达及其在子宫内膜癌中的临床病理意义。方法应用免疫组化检测30例正常增生期子宫内膜、27例非典型增生子宫内膜和43例子宫内膜癌组织中claudin-7和β-catenin的表达情况,统计分析它们与子宫内膜癌病理分级、临床分期、浸润深度及淋巴结转移等指标之间的关系,并对二者表达之间的关系进行探讨。结果在正常增生期子宫内膜、非典型增生子宫内膜和子宫内膜癌中,claudin-7的表达依次减低,阳性率分别为96.7%,66.7%和39.5%,三组之间具有显著差异（P〈0.05）;β-catenin在非典型增生子宫内膜和子宫内膜癌组织中的异位表达率分别为40.7%和74.4%,均显著高于正常增生期子宫内膜（3.3%）（P〈0.01）,子宫内膜癌组织中β-catenin的异位表达率显著高于非典型增生子宫内膜（P〈0.01）。在子宫内膜癌中,claudin-7的表达与临床分期、浸润深度和淋巴结转移有关（P〈0.01）;β-catenin的异位表达与病理分级、临床分期、浸润深度和淋巴结转移有关（P〈0.01）;Claudin-7的表达和β-catenin的异位表达呈显著负相关（r=-0.813,P〈0.01）。结论Claudin-7和β-catenin的异常表达与子宫内膜癌的发生发展有关,并且在此过程中claudin-7逐渐缺失以及β-catenin的异位表达可能对肿瘤的侵袭和转移产生一定作用。     

The levonorgestrel intrauterine system: therapeutic aspects

Use of the levonorgestrel-releasing intrauterine system (LNG IUS) is associated with a strong reduction in the number of days of bleeding and menstrual blood loss. This effect is based on the marked local action of the intrauterine release of levonorgestrel (LNG) on the endometrium. In suppressed endometrium the production of many highly active compounds ceases. On the other hand, LNG stimulates the synthesis of some regulatory proteins in the endometrium. Reduction of menstrual blood loss results in improvement of the body iron balance and in an increase in hemoglobin concentration. The LNG IUS has been used in the prevention and treatment of iron deficiency anemia. Many studies have demonstrated that the LNG IUS is effective in the treatment of menorrhagia. Reduction of excessive blood loss is seen as soon as the first menstruation after insertion, and at 1 year the reduction is more than 90%. The therapeutic effect is maintained for more than 5 years after first placement of the LNG IUS in the uterine cavity. Correct insertion is essential, and complications and side effects are rare; fertility is preserved, and invasive procedures such as endometrial ablation or hysterectomy and hospitalization are avoided. The third major indication for therapeutic use is in protection of the endometrium in estrogen replacement therapy during peri- and postmenopausal years. A fundal position of the system in the uterine cavity results in reduction of bleeding, and an increasing number of women have no bleeding at all during use of the IUS. Acceptance and continuation of use of the LNG IUS in hormone replacement therapy (HRT) have been high.